Clinical Trial Update: Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update on ORY-2001 for mild to moderate Alzheimer's disease, reporting safety and preliminary efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ORY-2001

Snippet

Sponsor: Oryzon Genomics S.A. | Conditions: Mild to Moderate Alzheimer's Disease | Phase 2 | Status: COMPLETED